Akari Therapeutics (AKTX) Other Operating Expenses (2015 - 2026)

Akari Therapeutics (AKTX) reported Other Operating Expenses of $12.1 million for Q1 2026, up 1333.98% sequentially from -$983000.0 in Q4 2024.

Akari Therapeutics (AKTX) Other Operating Expenses (2015 - 2026) Analysis & Trends

Akari Therapeutics (AKTX) has 3 years of Other Operating Expenses data on file, last reported at $12.1 million in Q1 2026.

For the quarter ending Q1 2026, Other Operating Expenses changed N/A year-over-year to $12.1 million; the trailing twelve-month figure through Mar 2026 stood at $12.1 million (up 1333.98% YoY), and the FY2025 full-year result was $5.2 million, up 200.64% from the prior year.
Other Operating Expenses rose to $12.1 million in Q1 2026, from -$983000.0 in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $12.1 million in Q1 2026 to a low of -$983000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Alnylam Pharmaceuticals	36.08 Bn	33.07 Bn	959.66 Mn

Download Data